Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study

• Published in: Investigational new drugs 2006-07, Vol.24 (4), p.335-341
• Main Authors: Whitehead, Robert P, McCoy, Sheryl, Macdonald, John S, Rivkin, Saul E, Neubauer, Marcus A, Dakhil, Shaker R, Lenz, Heinz-Josef, Tanaka, Michael S, Abbruzzese, James L
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Cancer therapies; Chemotherapy; Colorectal cancer; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Dose-Response Relationship, Drug; Female; Hemoglobin; Humans; Male; Medical prognosis; Metastasis; Middle Aged; Mutation; Neoplasm Staging; Neutropenia; Oncology; Ostomy; Patients; Probability; Proteins; Quinolones - adverse effects; Quinolones - therapeutic use; Southwestern United States; Survival Analysis; Toxicity; Tumors
• ISSN: 0167-6997; 1573-0646
• DOI: 10.1007/s10637-005-4345-3

The purpose of this Phase II multi-institutional trial was to determine the efficacy and toxicity of R115777 in previously untreated patients with metastatic colorectal carcinoma. Patients were required to have histologically confirmed colorectal cancer with distant metastatic disease that was not surgically curable. They could not have received prior chemotherapy for metastatic disease. R115777 was given at a dose of 300 mg p.o. twice a day for 21 days every 28 days until tumor progression or toxicity or other reason for discontinuation occurred. The primary endpoint was to determine the confirmed response probability with this treatment. There were 55 eligible patients accrued to the study. There were no complete responses, but one confirmed partial response for a confirmed response probability of 2% (95%CI 0-10%). Three additional patients had an unconfirmed partial response for an overall response probability of 7%. The time to treatment failure was 1.7 months and the estimated median survival was 8.1 months. One patient died of treatment related infection and there were 7 other patients with grade 4 toxicities consisting of neutropenia, leukopenia, febrile neutropenia and thrombocytopenia, depression, increased bilirubin, anemia, and pneumonitis/infiltrates. R115777 given as a single agent by this dose and schedule is ineffective in patients with metastatic colorectal cancer.